Patents by Inventor Janine Schuurman

Janine Schuurman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BINDING AGENTS BINDING TO EPCAM AND CD137
    Publication number: 20230295335
    Abstract: The present invention provides a binding agent that binds to EpCAM and to CD137 which is useful to treat or prevent a tumor or cancer, or to prevent progression of a tumor or cancer.
    Type: Application
    Filed: March 15, 2023
    Publication date: September 21, 2023
    Inventors: Andreea IOAN, Esther Cornelia Wilhelmina BREIJ, Lars GUELEN, David P.E. SATIJN, Ugur SAHIN, Alexander MUIK, Kristina SCHÖDEL, Sina FELLERMEIER-KOPF, Bart-Jan DE KREUK, Richard HIBBERT, Janine SCHUURMAN, Aran Frank LABRIJN
  • PRODUCTION OF HETERODIMERIC PROTEINS
    Publication number: 20230227495
    Abstract: The present invention relates to an in vitro method for production of heterodimeric proteins.
    Type: Application
    Filed: September 7, 2022
    Publication date: July 20, 2023
    Inventors: Michael GRAMER, Amitava Kundu, Ewald T. J. Van Den Bremer, Muriel Van Kampen, Patrick Priem, Aran Frank Labrijn, Joyce I. Meesters, Joost J. Neijssen, Janine Schuurman, Paul Parren, Patrick Van Berkel, Werner L. Vos, Amout F. Gerritsen
  • ANTIBODIES CAPABLE OF BINDING TO CD27, VARIANTS THEREOF AND USES THEREOF
    Publication number: 20230212301
    Abstract: The present invention relates to antibodies capable of binding to human CD27 and to variants thereof comprising a modified Fc region comprising one or more mutations that enhances the Fc-Fc interaction of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: November 14, 2022
    Publication date: July 6, 2023
    Inventors: Andreea Ioan, Frank Beurskens, Rob N. de Jong, Janine Schuurman, Esther C. W. Breij, Isil Altintas, Pauline L. de Goeje, David Satijn, Peter Boross, Ugur Sahin, Friederike Gieseke, Alexander Muik, Kristina Schödel
  • POLYPEPTIDE VARIANTS AND USES THEREOF
    Publication number: 20230107363
    Abstract: Described herein are polypeptides and antibodies comprising a variant Fc region. The variant Fc region provides for stabilized Fc-Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, while at the same time also having decreased complement-dependent cytotoxicity (CDC) and may also have decreased activation of other effector functions resulting from one or more amino acid modifications in the Fc region.
    Type: Application
    Filed: May 16, 2022
    Publication date: April 6, 2023
    Inventors: Rob DE JONG, Frank Beurskens, Marije Overdijk, Kristin STRUMANE, Janine Schuurman, Paul Parren
  • ANTIBODIES CAPABLE OF BINDING TO CD27, VARIANTS THEREOF AND USES THEREOF
    Publication number: 20230109496
    Abstract: The present invention relates to antibodies capable of binding to human CD27 and to variants thereof comprising a modified Fc region comprising one or more mutations that enhances the Fc-Fc interaction of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: September 6, 2022
    Publication date: April 6, 2023
    Inventors: Andreea Ioan, Frank Beurskens, Rob N. de Jong, Janine Schuurman, Esther C. W. Breij, Isil Altintas, Pauline L. de Goeje, David Satijn, Peter Boross, Ugur Sahin, Friederike Gieseke, Alexander Muik, Kristina Schödel
  • Humanized or chimeric CD3 antibodies
    Patent number: 11613575
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: March 28, 2023
    Assignee: GENMAB A/S
    Inventors: Edward Norbert Van Den Brink, Joost J. Neijssen, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Isil Altintas, Paul Parren, Rik Rademaker
  • Bispecific antibodies against HER2 and CD3
    Patent number: 11578141
    Abstract: Bispecific antibodies which comprise one antigen-binding region binding to an epitope of human epidermal growth factor receptor 2 (HER2) and one antigen-binding region binding to human CD3, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods for preparing and using the antibodies are also disclosed.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: February 14, 2023
    Assignee: GENMAB A/S
    Inventors: Joost J. Neijssen, Joyce I. Meesters, Bart De Goeij, Aran Frank Labrijn, Paul Parren, Janine Schuurman
  • HUMANIZED OR CHIMERIC CD3 ANTIBODIES
    Publication number: 20230027394
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Application
    Filed: May 9, 2022
    Publication date: January 26, 2023
    Inventors: Rik RADEMAKER, Isil Altintas, Patrick Engelberts, Janine Schuurman, Paul Parren
  • ANTI-DEATH RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220411522
    Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind antigens of Death Receptors, which are members of the tumor necrosis factor (TNF) receptor Superfamily (TNFR-SF) with an intracellular death domain. The invention relates in particular to antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after target binding. The invention further relates to a combination of antibody molecules binding different epitopes on one or more specific Death Receptors. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.
    Type: Application
    Filed: March 1, 2022
    Publication date: December 29, 2022
    Inventors: Frank BEURSKENS, Marije OVERDIJK, Rob DE JONG, David SATIJN, Kristin STRUMANE, Janine SCHUURMAN, Paul PARREN
  • ANTIBODY VARIANT COMBINATIONS AND USES THEREOF
    Publication number: 20220411529
    Abstract: The invention relates to combination therapy involving two or more antibodies, wherein the Fc regions of the two antibodies have been modified such that hetero-oligomerization between the antibodies is strongly favored over self-oligomerization when antibodies are bound to their corresponding target antigens and such that hetero-oligomerization-independent effector functions of one or both antibodies are eliminated or strongly reduced. The invention also relates to antibodies, compositions, and kits suitable for use in the combination therapy of the invention.
    Type: Application
    Filed: November 6, 2020
    Publication date: December 29, 2022
    Inventors: Rob DE JONG, Frank BEURSKENS, Gijs ZOM, Janine SCHUURMAN, Xiaoguang XUE
  • RECOMBINANT MONOVALENT ANTIBODIES AND METHODS FOR PRODUCTION THEREOF
    Publication number: 20220396629
    Abstract: The present invention provides monovalent antibodies with a long half-life when administered in vivo, methods of making such monovalent antibodies, pharmaceutical compositions comprising such antibodies, and uses of the monovalent antibodies.
    Type: Application
    Filed: May 26, 2022
    Publication date: December 15, 2022
    Inventors: Paul PARREN, Janine Schuurman, Tom Vink, Willem Karel Bleeker, Jan Van De Winkel, Patrick Van Berkel, Frank Beurskens
  • HUMANIZED OR CHIMERIC CD3 ANTIBODIES
    Publication number: 20220389101
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Application
    Filed: May 9, 2022
    Publication date: December 8, 2022
    Inventors: Rik RADEMAKER, Isil ALTINTAS, Patrick ENGELBERTS, Janine SCHUURMAN, Paul PARREN
  • HUMANIZED OR CHIMERIC CD3 ANTIBODIES
    Publication number: 20220380464
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Application
    Filed: May 9, 2022
    Publication date: December 1, 2022
    Inventors: Rik RADEMAKER, Isil ALTINTAS, Patrick ENGELBERTS, Janine SCHUURMAN, Paul PARREN
  • Monoclonal antibodies against c-Met
    Patent number: 11512140
    Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Grant
    Filed: August 23, 2019
    Date of Patent: November 29, 2022
    Assignee: GENMAB A/S
    Inventors: Joost J. Neijssen, Bart De Goeij, Edward Norbert Van Den Brink, Aran Frank Labrijn, Rene Hoet, Janine Schuurman, Paul Parren, Jan Van De Winkel
  • Production of heterodimeric proteins
    Patent number: 11492371
    Abstract: The present invention relates to an in vitro method for production of heterodimeric proteins.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: November 8, 2022
    Assignee: GENMAB A/S
    Inventors: Michael Gramer, Amitava Kundu, Ewald T. J. Van Den Bremer, Muriel Van Kampen, Patrick Priem, Aran Frank Labrijn, Joyce I. Meesters, Joost J. Neijssen, Janine Schuurman, Paul Parren, Patrick Van Berkel, Werner L. Vos, Arnout F. Gerritsen
  • Inert format
    Patent number: 11485796
    Abstract: Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: November 1, 2022
    Assignee: GENMAB A/S
    Inventors: Aran Frank Labrijn, Joyce I. Meesters, Joost J. Neijssen, Edward Norbert Van Den Brink, Janine Schuurman, Paul Parren
  • ANTIBODIES AND METHODS OF USE THEREOF IN TREATMENT OF INFECTIOUS DISEASE
    Publication number: 20220332801
    Abstract: The present invention relates to antibody molecules that bind to Wall Teichoic Acid (WTA) or Capsular Polysaccharides (CP) such as Capsular Polysaccharides type 5 (CP5). The invention relates in particular to antibody molecules of the IgG isotype having a mutation in the Fc domain that enhances clustering of IgG molecules after target binding.
    Type: Application
    Filed: November 24, 2021
    Publication date: October 20, 2022
    Inventors: Annemarie KUIPERS, Kok VAN KESSEL, Frank BEURSKENS, Rob DE JONG, Kristin STRUMANE, Janine SCHUURMAN, Paul PARREN, Jos VAN STRIJP, Suzan ROOIJAKKERS
  • Humanized or chimeric CD3 antibodies
    Patent number: 11359015
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: June 14, 2022
    Assignee: GENMAB A/S
    Inventors: Rik Rademaker, Isil Altintas, Patrick Engelberts, Janine Schuurman, Paul Parren
  • MONOCLONAL ANTIBODIES AGAINST HER2
    Publication number: 20220169738
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Application
    Filed: July 7, 2021
    Publication date: June 2, 2022
    Inventors: Bart DE GOEIJ, Simone DE HAIJ, Thilo RIEDL, Rene HOET, Ole BAADSGAARD, Jan VAN DE WINKEL, David SATIJN, Paul PARREN, Aran Frank LABRIJN, Joyce MEESTERS, Janine SCHUURMAN, Edward N. VAN DEN BRINK
  • Bispecific EGFR/C-Met Antibodies
    Publication number: 20210395373
    Abstract: Bispecific EGFR/c-Met antibodies and methods of making and using the molecules.
    Type: Application
    Filed: August 10, 2021
    Publication date: December 23, 2021
    Inventors: Mark Chiu, Sheri Moores, Joost Neijssen, Paul Parren, Janine Schuurman